CA
NZ
UK
AU
IND
US
The U.S. Food and Drug Administration’s proposed rule change could reshape drug manufacturing dynamics, benefiting contract development and manufacturing organizations (CDMOs) while tightening oversight of overseas production. The move aligns with broader efforts to reduce dependence on imported medicines and strengthen domestic supply chains, …
Amphastar Pharmaceuticals (NASDAQ: AMPH) has strengthened its governance structure by adding a new independent director. The move reflects the company’s ongoing efforts to enhance board oversight as it navigates the competitive pharmaceutical sector.
Key HighlightsRobert W. Baird lowered its price target for Circle Internet Group to $100 per share, down from $138.The adjustment reflects a reassessment of Circle Internet’s revenue trajectory, though BDMD’s direct exposure remains unclear.Investors reacted swiftly, with BDMD trading near its adjusted level in …
Concentra Group Holdings Parent, Inc. (NYSE: CON) reported a senior leadership transition that will affect its medical affairs function. Dr. John R.
Elite Health Systems Inc. Has launched a formal review of strategic alternatives as it grapples with intensifying competition and regulatory demands in the Medicare Advantage space. The move signals potential shifts in the company’s structure or ownership as it seeks to bolster its market …
Alto Neuroscience (NYSE: ANRO) recently shared financial and operational updates, emphasizing its commitment to advancing neuroscience-based therapeutics. The company’s latest disclosures highlight its focus on clinical innovation while maintaining a solid financial footing.
Astrana Health (NASDAQ: ASTH) has shared performance metrics for its accountable care organizations (ACOs) from 2024. The company submitted the data in a regulatory filing on July 13, 2026, offering investors a look at its operational progress. The filing includes a press release summarizing …
The mechanics behind the deal explain the reaction. To facilitate the exercise, Virax lowered the strike price to $6.00 per share, a price cut that effectively signals the company needed to sweeten the terms considerably to get existing preferred holders to convert. When a …
That distinction between p=0.020 for the overall population and p=0.006 for the severe subgroup is not a minor statistical footnote. A lower p-value indicates a stronger, more reliable signal, meaning the effect seen in high-severity patients is even less likely to be attributable to …
Statistical significance matters enormously in a market that has grown skeptical of small-sample, directional-but-inconclusive biotech data. A p=0.020 result tells investors this improvement is unlikely to be noise, and that distinction is often the difference between a stock that drifts and one that reprices …
Please wait processing your request...